ESD
gene geneOn this page
Summary
ESD (esterase D, HGNC:3465) is a protein-coding gene on chromosome 13q14.2, encoding S-formylglutathione hydrolase (P10768). Serine hydrolase involved in the detoxification of formaldehyde.
This gene encodes a serine hydrolase that belongs to the esterase D family. The encoded enzyme is active toward numerous substrates including O-acetylated sialic acids, and it may be involved in the recycling of sialic acids. This gene is used as a genetic marker for retinoblastoma and Wilson’s disease.
Source: NCBI Gene 2098 — RefSeq curated summary.
At a glance
- GWAS associations: 2
- Clinical variants (ClinVar): 43 total
- Druggable target: yes
- MANE Select transcript:
NM_001984
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:3465 |
| Approved symbol | ESD |
| Name | esterase D |
| Location | 13q14.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Ensembl gene | ENSG00000139684 |
| Ensembl biotype | protein_coding |
| OMIM | 133280 |
| Entrez | 2098 |
Gene structure
Transcript identifiers
Ensembl transcripts: 27 — 26 protein_coding, 1 protein_coding_CDS_not_defined
ENST00000378697, ENST00000378720, ENST00000412582, ENST00000471867, ENST00000495654, ENST00000898788, ENST00000898789, ENST00000898790, ENST00000898791, ENST00000898792, ENST00000898793, ENST00000898794, ENST00000898795, ENST00000898796, ENST00000898797, ENST00000898798, ENST00000898799, ENST00000898800, ENST00000898801, ENST00000898802, ENST00000898803, ENST00000898804, ENST00000898805, ENST00000928760, ENST00000928761, ENST00000961015, ENST00000961016
RefSeq mRNA: 1 — MANE Select: NM_001984
NM_001984
CCDS: CCDS9404
Canonical transcript exons
ENST00000378720 — 10 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001206384 | 46779935 | 46780033 |
| ENSE00001206408 | 46793397 | 46793444 |
| ENSE00001243184 | 46797105 | 46797161 |
| ENSE00001374216 | 46777456 | 46777623 |
| ENSE00001478488 | 46771256 | 46771496 |
| ENSE00003505896 | 46784252 | 46784350 |
| ENSE00003582989 | 46781496 | 46781615 |
| ENSE00003583001 | 46782667 | 46782791 |
| ENSE00003644672 | 46787021 | 46787109 |
| ENSE00003657237 | 46791346 | 46791420 |
Expression profiles
Bgee: expression breadth ubiquitous, 295 present calls, max score 99.06.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 99.6282 / max 1561.5565, expressed in 1819 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 137222 | 95.2309 | 1819 |
| 137223 | 4.3972 | 1621 |
Top tissues by expression
295 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| blood vessel layer | UBERON:0004797 | 99.06 | gold quality |
| popliteal artery | UBERON:0002250 | 98.98 | gold quality |
| tibial artery | UBERON:0007610 | 98.98 | gold quality |
| descending thoracic aorta | UBERON:0002345 | 98.95 | gold quality |
| hair follicle | UBERON:0002073 | 98.93 | gold quality |
| germinal epithelium of ovary | UBERON:0001304 | 98.89 | gold quality |
| aorta | UBERON:0000947 | 98.88 | gold quality |
| right coronary artery | UBERON:0001625 | 98.83 | gold quality |
| adrenal tissue | UBERON:0018303 | 98.83 | gold quality |
| choroid plexus epithelium | UBERON:0003911 | 98.81 | gold quality |
| cranial nerve II | UBERON:0000941 | 98.80 | gold quality |
| ganglionic eminence | UBERON:0004023 | 98.78 | gold quality |
| mucosa of stomach | UBERON:0001199 | 98.77 | gold quality |
| pigmented layer of retina | UBERON:0001782 | 98.77 | gold quality |
| saphenous vein | UBERON:0007318 | 98.76 | gold quality |
| thoracic aorta | UBERON:0001515 | 98.75 | gold quality |
| ventricular zone | UBERON:0003053 | 98.74 | gold quality |
| ascending aorta | UBERON:0001496 | 98.73 | gold quality |
| cauda epididymis | UBERON:0004360 | 98.70 | gold quality |
| left coronary artery | UBERON:0001626 | 98.67 | gold quality |
| superficial temporal artery | UBERON:0001614 | 98.66 | gold quality |
| coronary artery | UBERON:0001621 | 98.66 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 98.59 | gold quality |
| urethra | UBERON:0000057 | 98.58 | gold quality |
| parietal pleura | UBERON:0002400 | 98.49 | gold quality |
| heart right ventricle | UBERON:0002080 | 98.47 | gold quality |
| endocervix | UBERON:0000458 | 98.46 | gold quality |
| rectum | UBERON:0001052 | 98.45 | gold quality |
| body of uterus | UBERON:0009853 | 98.44 | gold quality |
| cortical plate | UBERON:0005343 | 98.39 | gold quality |
Single-cell (SCXA)
Detected in 5 experiment(s), a significant marker in 5.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-HCAD-4 | yes | 69.77 |
| E-MTAB-10287 | yes | 45.09 |
| E-MTAB-10042 | yes | 14.43 |
| E-CURD-122 | yes | 5.25 |
| E-ANND-3 | no | 0.00 |
Regulation
Is transcription factor: no
Upstream regulators (CollecTRI, top): MYC
miRNA regulators (miRDB)
12 targeting ESD, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-4668-3P | 100.00 | 68.74 | 2635 |
| HSA-MIR-3163 | 100.00 | 77.23 | 8605 |
| HSA-MIR-9983-3P | 99.94 | 71.48 | 3631 |
| HSA-MIR-6809-3P | 99.91 | 71.45 | 3814 |
| HSA-MIR-2052 | 99.79 | 69.37 | 2031 |
| HSA-MIR-6083 | 99.47 | 68.73 | 2393 |
| HSA-MIR-892C-5P | 99.16 | 70.56 | 2116 |
| HSA-MIR-7854-3P | 99.08 | 66.26 | 1117 |
| HSA-MIR-129-1-3P | 98.86 | 68.41 | 779 |
| HSA-MIR-129-2-3P | 98.86 | 68.41 | 779 |
| HSA-MIR-4257 | 97.86 | 68.05 | 1190 |
| HSA-MIR-625-3P | 97.32 | 66.55 | 554 |
Literature-anchored findings (GeneRIF, showing 6)
- The analysis involved the data on nine polymorphic codominant loci: HP, GC, TF, PI, PGM1, GLO1, C3, ACP1, and ESD. The loci were selected by significance of differences in genotype frequencies between tuberculosis patients and healthy controls (PMID:12942785)
- Autoantibodies to EsteD and BB-CK produced in experimental autoimmune uveoretinitis -induced mice were also detected in some endogenous uveitis patients, suggesting that these proteins might be autoantigens. (PMID:18552983)
- catalytic triad residues–Ser-153, His264, and Asp230–involved in catalysis. Mutagenesis of any of the catalytic triad residues to alanine abolished the enzyme activity. Backbone amides of Leu54 & Met150 are involved in the formation of the oxyanion hole (PMID:19126594)
- Abhydrolase domain-containing protein 11 and Esterase D predict the development of distant metastases and the presence of aggressive lung adenocarcinomas. (PMID:21596165)
- rs7996797 located on chr13q14.1-q14.2 near the ESD gene was the most significantly associated with hallux valgus in females in genome-wide association meta-analyses. (PMID:26337638)
- Esterase D interacts with metallothionein 2A and inhibits the migration of A549 lung cancer cells in vitro. (PMID:36649442)
Cross-species orthologs
5 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | esd | ENSDARG00000019496 |
| mus_musculus | Esd | ENSMUSG00000021996 |
| rattus_norvegicus | Esd | ENSRNOG00000009512 |
| drosophila_melanogaster | CG4390 | FBGN0038771 |
| caenorhabditis_elegans | Y48G10A.1 | WBGENE00013018 |
Protein
Protein identifiers
S-formylglutathione hydrolase — P10768 (reviewed: P10768)
Alternative names: Esterase D, Methylumbelliferyl-acetate deacetylase
All UniProt accessions (5): P10768, A0A140VJJ2, H7BZT7, U3KQT1, X6RA14
UniProt curated annotations — full annotation on UniProt →
Function. Serine hydrolase involved in the detoxification of formaldehyde.
Subunit / interactions. Homodimer.
Subcellular location. Cytoplasm. Cytoplasmic vesicle.
Polymorphism. There are two major electrophoretic isotypes. The sequence of the ESD*1 variant is shown.
Similarity. Belongs to the esterase D family.
RefSeq proteins (1): NP_001975* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000801 | Esterase-like | Family |
| IPR014186 | S-formylglutathione_hydrol | Family |
| IPR029058 | AB_hydrolase_fold | Homologous_superfamily |
Pfam: PF00756
Catalyzed reactions (Rhea), 2 shown:
- 4-methylumbelliferyl acetate + H2O = 4-methylumbelliferone + acetate + H(+) (RHEA:12208)
- S-formylglutathione + H2O = formate + glutathione + H(+) (RHEA:14961)
UniProt features (44 total): helix 14, strand 10, mutagenesis site 8, active site 3, modified residue 3, turn 2, sequence variant 2, initiator methionine 1, chain 1
Structure
Experimental structures (PDB)
1 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 3FCX | X-RAY DIFFRACTION | 1.5 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-P10768-F1 | 98.28 | 0.99 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Catalytic / active sites (3): 149 (charge relay system); 226 (charge relay system); 260 (charge relay system)
Post-translational modifications (3): 2, 4, 200
Mutagenesis-validated functional residues (8):
| Position | Phenotype |
|---|---|
| 54 | 83% of wild-type activity. |
| 149 | loss of activity. |
| 149 | 1.3% of wild-type activity. |
| 150 | 62% increase in activity. |
| 226 | 4.3% of wild-type activity. |
| 226 | 9% of wild-type activity. |
| 260 | 3% of wild-type activity. |
| 260 | 1.3% of wild-type activity. |
Function
Pathways and Gene Ontology
Reactome pathways
1 pathways
| ID | Pathway |
|---|---|
| R-HSA-156590 | Glutathione conjugation |
MSigDB gene sets: 201 (showing top):
MORF_DNMT1, REACTOME_BIOLOGICAL_OXIDATIONS, GCM_NPM1, MORF_RRM1, GOBP_ALDEHYDE_CATABOLIC_PROCESS, HSIAO_HOUSEKEEPING_GENES, DARWICHE_SKIN_TUMOR_PROMOTER_UP, DARWICHE_PAPILLOMA_RISK_LOW_UP, DARWICHE_PAPILLOMA_RISK_HIGH_UP, KYNG_DNA_DAMAGE_DN, KYNG_DNA_DAMAGE_BY_4NQO, DARWICHE_SQUAMOUS_CELL_CARCINOMA_UP, MORF_HDAC2, HNF1_Q6, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND
GO Biological Process (1): formaldehyde catabolic process (GO:0046294)
GO Molecular Function (7): hydrolase activity, acting on ester bonds (GO:0016788), S-formylglutathione hydrolase activity (GO:0018738), identical protein binding (GO:0042802), methylumbelliferyl-acetate deacetylase activity (GO:0047374), carboxylic ester hydrolase activity (GO:0052689), protein binding (GO:0005515), hydrolase activity (GO:0016787)
GO Cellular Component (5): endoplasmic reticulum lumen (GO:0005788), cytosol (GO:0005829), cytoplasmic vesicle (GO:0031410), extracellular exosome (GO:0070062), cytoplasm (GO:0005737)
Reactome top-level categories
Rollup of top-1 pathways:
| Category | Pathways |
|---|---|
| Phase II - Conjugation of compounds | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cytoplasm | 2 |
| cellular anatomical structure | 2 |
| small molecule catabolic process | 1 |
| aldehyde catabolic process | 1 |
| formaldehyde metabolic process | 1 |
| cellular detoxification of aldehyde | 1 |
| hydrolase activity | 1 |
| thiolester hydrolase activity | 1 |
| protein binding | 1 |
| deacetylase activity | 1 |
| carboxylic ester hydrolase activity | 1 |
| hydrolase activity, acting on ester bonds | 1 |
| binding | 1 |
| catalytic activity | 1 |
| endoplasmic reticulum | 1 |
| intracellular organelle lumen | 1 |
| intracellular vesicle | 1 |
| extracellular vesicle | 1 |
| intracellular anatomical structure | 1 |
Protein interactions and networks
STRING
1664 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| ESD | CES5A | Q6NT32 | 923 |
| ESD | CES2 | O00748 | 868 |
| ESD | CES3 | Q6UWW8 | 860 |
| ESD | ADH5 | P11766 | 847 |
| ESD | CES1 | P23141 | 791 |
| ESD | PGM1 | P36871 | 777 |
| ESD | HAGH | Q16775 | 756 |
| ESD | NDUFAB1 | O14561 | 721 |
| ESD | PGD | P52209 | 720 |
| ESD | SLC30A4 | O14863 | 713 |
| ESD | GLO1 | P78375 | 662 |
| ESD | LPA | P08519 | 638 |
| ESD | CP | P00450 | 634 |
| ESD | TFPI | P10646 | 588 |
| ESD | ACP1 | P24666 | 583 |
IntAct
52 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| FSD2 | ESD | psi-mi:“MI:0915”(physical association) | 0.870 |
| ESD | FSD2 | psi-mi:“MI:0915”(physical association) | 0.870 |
| ESD | ESD | psi-mi:“MI:0915”(physical association) | 0.740 |
| TK2 | psi-mi:“MI:0915”(physical association) | 0.400 | |
| ESD | PLCG2 | psi-mi:“MI:0915”(physical association) | 0.370 |
| ESD | CRK | psi-mi:“MI:0915”(physical association) | 0.370 |
| OTUB1 | EPM2A | psi-mi:“MI:0914”(association) | 0.350 |
| KSR1 | FBLL1 | psi-mi:“MI:0914”(association) | 0.350 |
| CAV1 | PPM1G | psi-mi:“MI:0914”(association) | 0.350 |
| CAV1 | ACOT7 | psi-mi:“MI:0914”(association) | 0.350 |
| MAP3K7 | ACOT7 | psi-mi:“MI:0914”(association) | 0.350 |
| RIPK4 | TBCA | psi-mi:“MI:0914”(association) | 0.350 |
| MYLK | ACOT7 | psi-mi:“MI:0914”(association) | 0.350 |
| MYLK4 | AP3D1 | psi-mi:“MI:0914”(association) | 0.350 |
| CDKL3 | psi-mi:“MI:0914”(association) | 0.350 | |
| PRKD2 | ACOT7 | psi-mi:“MI:0914”(association) | 0.350 |
| DDA1 | PGK1 | psi-mi:“MI:0914”(association) | 0.350 |
| ACTR2 | psi-mi:“MI:0914”(association) | 0.350 | |
| ESD | PIKFYVE | psi-mi:“MI:0914”(association) | 0.350 |
| MBNL1 | SAP30 | psi-mi:“MI:0914”(association) | 0.350 |
| SAR1B | UBA6 | psi-mi:“MI:0914”(association) | 0.350 |
| FSD2 | MID1 | psi-mi:“MI:0914”(association) | 0.350 |
| FSD2 | MYO9A | psi-mi:“MI:0914”(association) | 0.350 |
| VCAM1 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (93): ESD (Two-hybrid), FSD2 (Two-hybrid), ESD (Co-fractionation), ESD (Co-fractionation), ESD (Co-fractionation), ESD (Co-fractionation), ESD (Co-fractionation), ESD (Co-fractionation), ESD (Co-fractionation), ESD (Co-fractionation), ESD (Co-fractionation), ESD (Co-fractionation), ESD (Co-fractionation), ESD (Co-fractionation), ESD (Co-fractionation)
ESM2 similar proteins: A0A0H2URB1, A1A834, A1AD14, A1AXZ2, A7ZIA3, A7ZNX7, A7ZX03, A8A215, A8FRR2, B0BNE5, B1IYB5, B1J086, B1LIP0, B1LKQ1, B1X7P2, B1XEU8, B4S5S1, P10768, P23553, P29368, P33018, P36838, P40363, P44556, P46544, P51025, P63731, P63732, P76049, P94388, Q08E20, Q0T2X0, Q0TFT6, Q0TKS8, Q1R9R8, Q1RFI8, Q31YW2, Q32EQ3, Q3Z052, Q3Z551
Diamond homologs: A1A834, A1AD14, A1AXZ2, A7ZIA3, A7ZNX7, A7ZX03, A8A215, B0BNE5, B1IYB5, B1J086, B1LIP0, B1LKQ1, B1X7P2, B1XEU8, P10768, P33018, P40363, P44556, P51025, Q08E20, Q0T2X0, Q0TFT6, Q0TKS8, Q1R9R8, Q1RFI8, Q31YW2, Q32EQ3, Q3Z052, Q3Z551, Q8FFU3, Q8FKG2, Q8LAS8, Q8X5J5, Q8X635, Q9GJT2, Q9R0P3
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
43 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 34 |
| Likely benign | 0 |
| Benign | 2 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1302 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 13:46777447:AATAC:A | donor_loss | 1.0000 |
| 13:46777448:ATACT:A | donor_loss | 1.0000 |
| 13:46777449:TACTT:T | donor_loss | 1.0000 |
| 13:46777450:ACT:A | donor_loss | 1.0000 |
| 13:46777451:C:CG | donor_loss | 1.0000 |
| 13:46777452:TT:T | donor_loss | 1.0000 |
| 13:46777453:TGC:T | donor_loss | 1.0000 |
| 13:46777455:CCT:C | donor_gain | 1.0000 |
| 13:46777619:TAAGC:T | acceptor_gain | 1.0000 |
| 13:46777620:AAGC:A | acceptor_gain | 1.0000 |
| 13:46777621:AGC:A | acceptor_gain | 1.0000 |
| 13:46777621:AGCCT:A | acceptor_loss | 1.0000 |
| 13:46777622:GC:G | acceptor_gain | 1.0000 |
| 13:46777623:CCTG:C | acceptor_gain | 1.0000 |
| 13:46777624:C:A | acceptor_loss | 1.0000 |
| 13:46777624:C:CC | acceptor_gain | 1.0000 |
| 13:46777625:T:G | acceptor_loss | 1.0000 |
| 13:46777626:G:C | acceptor_gain | 1.0000 |
| 13:46777626:G:GC | acceptor_gain | 1.0000 |
| 13:46780030:CAGA:C | acceptor_gain | 1.0000 |
| 13:46780034:C:CC | acceptor_gain | 1.0000 |
| 13:46780037:C:CT | acceptor_gain | 1.0000 |
| 13:46780038:A:T | acceptor_gain | 1.0000 |
| 13:46780043:C:CT | acceptor_gain | 1.0000 |
| 13:46781494:A:AC | donor_gain | 1.0000 |
| 13:46781495:C:CC | donor_gain | 1.0000 |
| 13:46782662:ATTAC:A | donor_loss | 1.0000 |
| 13:46782663:TTAC:T | donor_loss | 1.0000 |
| 13:46782664:TA:T | donor_loss | 1.0000 |
| 13:46782665:A:C | donor_loss | 1.0000 |
AlphaMissense
1864 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 13:46771485:A:C | H260Q | 0.998 |
| 13:46771485:A:T | H260Q | 0.998 |
| 13:46781552:A:G | S149P | 0.998 |
| 13:46771487:G:C | H260D | 0.997 |
| 13:46777540:A:C | F228L | 0.996 |
| 13:46777540:A:T | F228L | 0.996 |
| 13:46777542:A:G | F228L | 0.996 |
| 13:46777548:C:G | D226H | 0.996 |
| 13:46782733:A:C | F105L | 0.996 |
| 13:46782733:A:T | F105L | 0.996 |
| 13:46782735:A:G | F105L | 0.996 |
| 13:46784256:G:C | S84R | 0.996 |
| 13:46784256:G:T | S84R | 0.996 |
| 13:46784258:T:G | S84R | 0.996 |
| 13:46777523:A:G | L234S | 0.995 |
| 13:46777547:T:A | D226V | 0.995 |
| 13:46777557:C:A | G223W | 0.995 |
| 13:46781557:C:T | G147D | 0.995 |
| 13:46784340:G:C | C56W | 0.995 |
| 13:46777466:C:G | R253P | 0.994 |
| 13:46781545:C:T | G151E | 0.994 |
| 13:46781553:G:C | H148Q | 0.994 |
| 13:46781553:G:T | H148Q | 0.994 |
| 13:46781555:G:C | H148D | 0.994 |
| 13:46784347:A:G | L54S | 0.994 |
| 13:46784350:C:T | G53D | 0.994 |
| 13:46787021:C:G | G53R | 0.994 |
| 13:46777557:C:G | G223R | 0.993 |
| 13:46777557:C:T | G223R | 0.993 |
| 13:46780007:G:C | C176W | 0.993 |
dbSNP variants (sampled 300 via entrez): RS1000401908 (13:46791434 G>C), RS1000408001 (13:46798723 A>C,G), RS1000455072 (13:46784546 C>T), RS1000465190 (13:46798099 G>A), RS1000526282 (13:46784187 A>G), RS1000703416 (13:46777828 C>A), RS1000752977 (13:46791774 T>C), RS1000810591 (13:46796215 C>A), RS1000926398 (13:46795821 C>T), RS1001293655 (13:46788062 T>C), RS1001342004 (13:46772969 C>G,T), RS1001560700 (13:46773454 A>C), RS1001638335 (13:46780345 A>C,G), RS1001807038 (13:46792288 A>G), RS1002022692 (13:46799364 A>G)
Disease associations
OMIM: gene MIM:133280 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
2 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST006585_2486 | Blood protein levels | 1.000000e-07 |
| GCST009391_713 | Metabolite levels | 9.000000e-06 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0010531 | S-adenosylhomocysteine measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: yes
ChEMBL targets (1): CHEMBL2189130 (SINGLE PROTEIN)
PharmGKB: 1 entry (VIP=true, CPIC=false)
ChEMBL bioactivities
3 potent at pChembl≥5 of 3 total, top 3 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).
| pChembl | Type | Value | Unit | Molecule |
|---|---|---|---|---|
| 9.10 | Kd | 0.8 | nM | CHEMBL4635246 |
| 6.93 | Kd | 116.5 | nM | CHEMBL5653589 |
| 6.93 | ED50 | 116.5 | nM | CHEMBL5653589 |
PubChem BioAssay actives
2 with measured affinity, of 16 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.
| Compound | Assay | Type | Value | Unit |
|---|---|---|---|---|
| 4-chloro-2-(3-phenyl-2-pyridin-2-yl-3,4-dihydropyrazol-5-yl)phenol | 1662249: Binding affinity to human ESD expressed in HEK293T cells assessed as dissociation constant | kd | 0.0008 | uM |
| 4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide | 2148341: Binding affinity to human ESD incubated for 45 mins by Kinobead based pull down assay | kd | 0.1164 | uM |
CTD chemical–gene interactions
59 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Cadmium Chloride | increases abundance, increases expression, decreases expression | 4 |
| bisphenol A | decreases expression, increases expression | 3 |
| sodium arsenite | increases abundance, increases expression, decreases expression | 3 |
| Valproic Acid | affects expression, increases expression | 3 |
| Cadmium | decreases expression, increases abundance, increases expression | 2 |
| aristolochic acid I | decreases expression, increases expression | 1 |
| bisphenol F | increases expression | 1 |
| TAK-243 | increases sumoylation | 1 |
| dicrotophos | decreases expression | 1 |
| methylmercuric chloride | decreases expression | 1 |
| beta-lapachone | increases expression | 1 |
| arsenite | affects binding, increases reaction | 1 |
| methylparaben | decreases expression | 1 |
| perfluorooctanoic acid | increases expression | 1 |
| sulindac sulfide | increases expression | 1 |
| potassium chromate(VI) | affects cotreatment, decreases expression | 1 |
| epigallocatechin gallate | affects cotreatment, decreases expression | 1 |
| microcystin RR | decreases expression | 1 |
| glycidamide | increases expression | 1 |
| K 7174 | decreases expression | 1 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | affects cotreatment, increases expression | 1 |
| nutlin 3 | affects cotreatment, increases secretion | 1 |
| pentabrominated diphenyl ether 100 | decreases expression | 1 |
| hexabrominated diphenyl ether 153 | decreases expression | 1 |
| 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide | increases expression | 1 |
| STA 9090 | increases expression | 1 |
| jinfukang | decreases expression | 1 |
| LDN 193189 | affects cotreatment, increases expression | 1 |
| bisphenol AF | increases expression | 1 |
| Temozolomide | decreases expression | 1 |
ChEMBL screening assays
15 unique, capped per target: 15 binding
Representative assays (with source publication via chembl_document):
| Assay ID | Type | Description | Source paper |
|---|---|---|---|
| CHEMBL2209086 | Binding | Inhibition of ESD binding to FP-biotin in [12C][14N]-lysine, arginine and [13C6][15N2]-lysine, arginine labeled HEK293T cells at 20 uM after 1 hr by isotopic activity-based protein profiling-MudPIT assay | Discovery and optimization of sulfonyl acrylonitriles as selective, covalent inhibitors of protein phosphatase methylesterase-1. — J Med Chem |
Cellosaurus cell lines
1 cell lines: 1 transformed cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_B2WQ | Abcam HEK293T ESD KO | Transformed cell line | Female |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.